These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 27998799

  • 1. Phospholipid complex enriched micelles: A novel drug delivery approach for promoting the antidiabetic effect of repaglinide.
    Kassem AA, Abd El-Alim SH, Basha M, Salama A.
    Eur J Pharm Sci; 2017 Mar 01; 99():75-84. PubMed ID: 27998799
    [Abstract] [Full Text] [Related]

  • 2. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
    Rawat MK, Jain A, Singh S.
    J Pharm Sci; 2011 Jun 01; 100(6):2366-78. PubMed ID: 21491449
    [Abstract] [Full Text] [Related]

  • 3. Preparation, characterization and in vivo evaluation of antihyperglycemic activity of microwave generated repaglinide solid dispersion.
    Zawar LR, Bari SB.
    Chem Pharm Bull (Tokyo); 2012 Jun 01; 60(4):482-7. PubMed ID: 22466731
    [Abstract] [Full Text] [Related]

  • 4. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.
    Rawat MK, Jain A, Mishra A, Muthu MS, Singh S.
    Ther Deliv; 2010 Jul 01; 1(1):63-73. PubMed ID: 22816120
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier.
    Yin LF, Huang SJ, Zhu CL, Zhang SH, Zhang Q, Chen XJ, Liu QW.
    Drug Dev Ind Pharm; 2012 Nov 01; 38(11):1371-80. PubMed ID: 22296267
    [Abstract] [Full Text] [Related]

  • 6. In vitro characterization and invivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles.
    Dhana Lekshmi UM, Poovi G, Kishore N, Reddy PN.
    Int J Pharm; 2010 Aug 30; 396(1-2):194-203. PubMed ID: 20600729
    [Abstract] [Full Text] [Related]

  • 7. Hydrogels based on interpenetrating network of chitosan and polyvinyl pyrrolidone for pH-sensitive delivery of repaglinide.
    Vaghani SS, Patel MM.
    Curr Drug Discov Technol; 2011 Jun 30; 8(2):126-35. PubMed ID: 21513486
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of solubility and antidiabetic effects of Repaglinide using spray drying technique in STZ-induced diabetic rats.
    Varshosaz J, Minayian M, Ahmadi M, Ghassami E.
    Pharm Dev Technol; 2017 Sep 30; 22(6):754-763. PubMed ID: 26895041
    [Abstract] [Full Text] [Related]

  • 9. Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation.
    Singh C, Bhatt TD, Gill MS, Suresh S.
    Int J Pharm; 2014 Jan 02; 460(1-2):220-7. PubMed ID: 24188983
    [Abstract] [Full Text] [Related]

  • 10. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid.
    Dora CP, Kushwah V, Katiyar SS, Kumar P, Pillay V, Suresh S, Jain S.
    Int J Pharm; 2017 Dec 20; 534(1-2):1-13. PubMed ID: 28970115
    [Abstract] [Full Text] [Related]

  • 11. A study on ethosomes as mode for transdermal delivery of an antidiabetic drug.
    Bodade SS, Shaikh KS, Kamble MS, Chaudhari PD.
    Drug Deliv; 2013 Dec 20; 20(1):40-6. PubMed ID: 23311652
    [Abstract] [Full Text] [Related]

  • 12. Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method.
    Rawat MK, Jain A, Mishra A, Muthu MS, Singh S.
    Curr Drug Deliv; 2010 Jan 20; 7(1):44-50. PubMed ID: 20044909
    [Abstract] [Full Text] [Related]

  • 13. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats.
    Rawat MK, Jain A, Singh S.
    J Pharm Sci; 2011 Jun 20; 100(6):2406-17. PubMed ID: 21491451
    [Abstract] [Full Text] [Related]

  • 14. Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo.
    Yue PF, Yuan HL, Xie H, Xiao XH, Yang M, Liao MX, Zhu WF, Cai PL.
    Drug Dev Ind Pharm; 2008 Jul 20; 34(7):708-18. PubMed ID: 18612911
    [Abstract] [Full Text] [Related]

  • 15. Porous carrier based floating granular delivery system of repaglinide.
    Jain SK, Agrawal GP, Jain NK.
    Drug Dev Ind Pharm; 2007 Apr 20; 33(4):381-91. PubMed ID: 17523003
    [Abstract] [Full Text] [Related]

  • 16. Poloxamer 407 microspheres for orotransmucosal drug delivery. Part I: formulation, manufacturing and characterization.
    Albertini B, Passerini N, Di Sabatino M, Monti D, Burgalassi S, Chetoni P, Rodriguez L.
    Int J Pharm; 2010 Oct 31; 399(1-2):71-9. PubMed ID: 20696227
    [Abstract] [Full Text] [Related]

  • 17. Development and characterization of a novel lipohydrogel nanocarrier: repaglinide as a lipophilic model drug.
    Ebrahimi HA, Javadzadeh Y, Hamidi M, Barzegar Jalali M.
    J Pharm Pharmacol; 2016 Apr 31; 68(4):450-8. PubMed ID: 27114047
    [Abstract] [Full Text] [Related]

  • 18. Preparation of a nanoscale dihydromyricetin-phospholipid complex to improve the bioavailability: in vitro and in vivo evaluations.
    Zhao X, Shi C, Zhou X, Lin T, Gong Y, Yin M, Fan L, Wang W, Fang J.
    Eur J Pharm Sci; 2019 Oct 01; 138():104994. PubMed ID: 31302210
    [Abstract] [Full Text] [Related]

  • 19. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin.
    Liu M, Cao W, Sun Y, He Z.
    Int J Pharm; 2014 Dec 30; 477(1-2):159-66. PubMed ID: 25455768
    [Abstract] [Full Text] [Related]

  • 20. Preparation, characterization and tableting of cilnidipine solid dispersions.
    Hu L, Song W, Niu F, Jiao K, Jia Z.
    Pak J Pharm Sci; 2013 May 30; 26(3):629-36. PubMed ID: 23625441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.